Evaluation Of NMP22 In Detection Of Transitional Cell Carcinoma Of The Bladder

Purpose: To assess the clinical value of urinary level of nuclear matrix protein 22(NMP22) as a novel, non-invasive, effective and rapid mode tumor marker for the diagnosis of original and recurrent bladder. We also evaluated and compared the sensitivity of bladder wash cytology.Methods: 38 patients with original blander cancer, 20 patients with recurrent blander cancer and 20 healthy volunteers were recruited from January 2001 to March 2004. All bladder cancer patients provided voided urine samples preopratively. Standard ELISA (enzyme-linked immunosorbent assay) was used to determine the quantity of nuclear matrix protein (NMP-22) in urine of all bladder cancer patients. 30 of 38 patients with original bladder cancer were determined for urinary NMP22 value at 7 days postoperatively again. Bladder wash cytology was done at cystoscopy.Results: The median NMP22 value of original bladder cancer was 28.3 × 10~3 U/L and recurrent blander cancer was 14.5 × 10~3 U/L, respectively. Both of which were significantly higher then healthy volunteers 2.6 × 10~3 U/L (P<0.001). Tumor stage had a statistically significant influence on NMP22 (r_s=0.643,P<0.001), but tumor grade had not. The NMP22 value of patients with original bladder cancer was elevated with tumors pathologic grades increase. For 30 patients with original bladder cancer determined againpostoperatively, and their median urinary NMP22 value was 1.30 + 2.80, decreasing remarkably in comparison with that of preoperation (P<0.01). The positive rate of NMP22 is much higher than cytology in patients with original bladder cancer (PO.001).Conclusion: Urinary NMP22 is a high sensitivity and specificity, simple, noninvasive tumor marker for the diagnosis of blander cancer and can indicate tumor malignancy degree and prognosis, which may reduce the frequency of patients needing to undergo conventional invasive cystoscopy.(1) NMP22 as a tumor marker is sensitive for the diagnosis of blander cancer.(2) NMP22 value was associated with tumor stage, but not with grade.(3) NMP22 could evaluate the operative effect of blander cancer.(4) NMP22 was one of the predictor to the recurrence of blander cancer after operation.(5) The suitable value of NMP22 was 10X 103U/L in original bladder cancer, but in recurrent blander cancer it was decreased to 6.4 X 103U/L.(6) Cytology was not good enough able to distinguish patients with bladder cancer when compared with NMP22.